$6.86
+1.3%Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Chief Executive Officer, President & Director
Compensation
$906,164
Chief Financial Officer & Principal Accounting Officer
Compensation
$598,045
Chief Medical Officer
Compensation
$669,064
Co-Founder
Co-Founder
General Counsel & Chief Compliance Officer
Senior Vice President of New Products
Senior Vice President of Research & Development
During the last 12 months, insiders have purchased $1.31M and sold $1.17M worth of SGMT shares, resulting in $141K of net buying activity.
0
0.00
0
0.00
+0
+$0
0
0.00
19.7K
105.46K
-105K
-$105K
0
0.00
37.7K
289.98K
-290K
-$290K
244.3K
1.31M
84.5K
772.19K
+537K
+$537K
Seidenberg Beth C
Director
$330K
Hoelscher Paul W.
Director
$172K
Grammer Elizabeth A
Director
$172K
Kemble George
Director
$172K
Walbert Timothy P
Director
$172K
Happel David
Director, Officer: President & Ceo
$663K
Kemble George
Director, Officer: Executive Chairman
$290K
Rozek Elizabeth
Officer: Chief Legal & Admin. Officer
$113K
Martins Eduardo Bruno
Officer: Chief Medical Officer
$95K
Chauche Thierry
Officer: Chief Financial Officer
$7K
Moderately bullish with $141K net buying. Insiders show cautious optimism through measured share purchases.
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
SGMT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 21, 2026 | June 12, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2025 | June 09, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 18, 2024 | June 05, 2024 | 2024 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.